Repeat Renal Biopsies in Proteinuric Patients with Membranous Nephropathy Following Therapy

Overview

About this study

The purpose of this study is to evaluate the role of an antibody, called anti-PLA2R, in detecting disease in patients with membranous nephropathy (MN) who remain proteinuric despite being treated with immunosuppressive drugs.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Age ≥ 18
Biopsy proven primary membranous nephropathy with positive anti-PLA2R at time of biopsy (either blood or on renal biopsy)
Has received disease-specific treatment for the MN
Proteinuria (≥1 gram/24 hours) 24 months after immunosuppressive therapy initiated
Serum creatinine < 3mg/dl
Able to provide consent
Anti-PLA2R level at 24 months
BP <150/90 mm Hg at the screening visit

Exclusion Criteria

Secondary membranous nephropathy (lupus or cancer-related)
Serum creatinine ≥3mg/dl
Patients positive hepatitis B and/or C within 3 years of enrollment
Any contra-indications to perform renal biopsy safely (increased risk of bleed such as anticoagulation)
Pregnancy
Unable to consent

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Ladan Zand, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Ladan Zand, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials